# Theravance Biopharma Inc. (TBPH) fundamentals

Data as of 2026-09-08. NASDAQ, United States. Sector: Healthcare / Biotechnology. Price $17.08, market value $887 million.

## Valuation
- **P/E (trailing): 16.4×** (5-yr avg 5.0×, 3-yr avg 9.1×). Theravance Biopharma Inc. trades at 16.4× trailing earnings, well above its own five-year average of 5.0×: investors are paying up relative to the company's past. The Healthcare median in the September 2026 study was 28.5×. Forward P/E is 13.4×, lower than trailing, so analysts expect earnings to grow.
- **PEG: 0.05**. A PEG of 0.05 means the P/E is low relative to expected earnings growth: the market is not paying much for that growth.
- **Price / sales: 8.5×**. Each dollar of revenue is priced at 8.5×.
- **Price / book: 3.1×**. The shares trade at 3.1× book value; book value is a meaningful part of the valuation.
- **Earnings yield: 6.1%**. The inverse of the P/E: 6.1% of the price is earned each year.

## Profitability
- **Operating margin: -4.0%**. Operating margin is negative: the business loses money before interest and tax.
- **Net margin: 98.5%**. 98.5% of each dollar of sales reaches the bottom line.
- **Return on equity: 35.7%**. 35.7% on shareholders' equity is excellent if it is not driven by leverage; sustained above 20% usually signals a competitive advantage.
- **Return on invested capital: -2.6%**. Return on all capital, debt included, is -2.6%: close to or below the cost of capital, so growth may not create value.
- **Return on assets: 11.1%**. Each dollar of assets produces 11.1% of profit.

## Growth
- **Revenue growth (1 yr): 66.9%** (3-yr 27.9%/yr, 5-yr 8.4%/yr). Revenue grew 66.9% over the last year, against 8.4% a year compounded over five years: growth is accelerating.
- **EPS growth (1 yr): 279.1%** (3-yr -44.2%/yr). Earnings per share rose 279.1%, faster than revenue, so margins expanded or the share count shrank.

## Financial health
- **Debt to equity: 0.00**. Debt is 0.00 times equity: a conservative balance sheet.
- **Current ratio: 10.93** (quick 10.93). Current assets cover the next year's liabilities 10.93 times.
- **Piotroski F-score: 7/9**. 7 of 9 fundamental checks pass: strong and improving financials.

## Dividends
- **Dividend: none**. Theravance Biopharma Inc. does not currently pay a dividend.

## Price and momentum
- **Total return (1 yr): 21.6%** (YTD -8.7%, 3-mo 4.8%). The shares are up 21.6% over twelve months including dividends.
- **From 52-week high: -18.8%** (30.6% above the low). Trading 19% below its 52-week high.
- **200-day average: below**. The price sits below its 200-day moving average, the usual definition of a downtrend.
- **RSI (14-day): 65**. An RSI of 65 is neutral.
- **Beta (1 yr): 0.61** (volatility 45%). Beta of 0.61 against the S&P 500: the shares move much less than the market.

Live score and charts: https://foliofundamentals.com/analyzer?s=TBPH · Page: https://foliofundamentals.com/stocks/tbph

Not investment advice.